Joan Schmidt - DBV Technologies Executive Vice President General Counsel
| DBV Stock | EUR 1.25 0.02 1.57% |
President
Ms. Joan Schmidt is Executive Vice President, General Counsel of the Company. Joan Schmidt joins DBV after three years at Biotronik, a global medical device company, where she was Executive Vice President, Legal Human Resources, General Counsel and Secretary. Previously, she held various positions of increasing responsibility at Novo Nordisk, most recently as Corporationrationrate Vice President, Legal Affairs. Earlier in her career, she was an associate in the litigation group of a private law firm in New York, NY. Joan earned a J.D. from Pace University and a B.A. from the University of Connecticut. since 2018.
| Age | 54 |
| Tenure | 6 years |
| Phone | 33 1 55 42 78 78 |
| Web | https://www.dbv-technologies.com |
DBV Technologies Management Efficiency
The company has return on total asset (ROA) of (0.2178) % which means that it has lost $0.2178 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4299) %, meaning that it generated substantial loss on money invested by shareholders. DBV Technologies' management efficiency ratios could be used to measure how well DBV Technologies manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 12 records | PRESIDENT Age | ||
| Mathieu Simon | Cellectis | N/A | |
| Stephane Depil | Cellectis | N/A | |
| Nathalie Huitorel | Genfit | N/A | |
| Yannis Morel | Innate Pharma | 50 | |
| Jerome Tiollier | Innate Pharma | 58 | |
| Jennifer Butler | Innate Pharma | N/A | |
| Marcel Rozencweig | Innate Pharma | 70 | |
| William Monteith | Cellectis | 56 | |
| Bart Staels | Genfit | N/A | |
| Catherine Moukheibir | Innate Pharma | 56 | |
| Stefan Scherer | Cellectis | N/A | |
| Elsy Boglioli | Cellectis | N/A | |
Management Performance
| Return On Equity | -0.43 | |||
| Return On Asset | -0.22 |
DBV Technologies Leadership Team
Elected by the shareholders, the DBV Technologies' board of directors comprises two types of representatives: DBV Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DBV. The board's role is to monitor DBV Technologies' management team and ensure that shareholders' interests are well served. DBV Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DBV Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Pascale Ehouarn, Industrial Development and Production Director | ||
| Claude Thebault, Medical Director | ||
| Wence Agbotounou, Chief Clinical Trial Officer | ||
| Laurent Martin, Sr. Executive VP of Regulatory and Product Strategy | ||
| Viviane Monges, Non-Executive Independent Director | ||
| Caroline Daniere, Chief Human Resource Officer | ||
| Claire Giraut, Non-Executive Independent Director | ||
| Didier Hoch, Director | ||
| Adam Slatter, Chief Quality Officer | ||
| Daniel Tass, CEO Director | ||
| Daniel Soland, Non-Executive Independent Director | ||
| Julie ONeill, Non-Executive Director | ||
| Hugh Sampson, Chief Scientific Officer | ||
| Pascal Wotling, Chief Technical Operations Officer | ||
| Charles Ruban, Chief Development Officer | ||
| Nathalie Donne, Director of Bus. Devel. and Corporate Communication | ||
| Ramzi Benamar, Chief Financial Officer | ||
| Lucie Mondoulet, Director of Research | ||
| Anne Pollak, Head Relations | ||
| Chahra Louafi, Director - Representative of CDC Entreprises (Innobio) | ||
| Peter Hutt, Independent Director | ||
| Michele Robertson, Chief Legal Officer | ||
| Rafaele Tordjman, Director - Representative of Sofinnova Partners | ||
| Bertrand Dupont, Co-Founder and Sr. Executive VP of Technology | ||
| MarieCatherine Therene, Deputy Chief Executive Officer and Responsible Pharmacist | ||
| Joseph Becker, VP Communications | ||
| Sbastien Robitaille, Chief Officer | ||
| Veronique Foutel, Chief Strategic Marketing Officer | ||
| Daniel Tasse, Chief Executive Officer, Director | ||
| Rafale Tordjman, Director - Representative of Sofinnova Partners | ||
| Joan Schmidt, Executive Vice President General Counsel | ||
| George Horner, Director | ||
| Michael Goller, Non-Executive Director | ||
| Sebastien Robitaille, Chief Financial Officer | ||
| Torbjorn Bjerke, Non-Executive Independent Director | ||
| Pharis Mohideen, Chief Medical Officer | ||
| PierreHenri Benhamou, Chairman of the Board, CEO | ||
| Torbjrn Bjerke, Independent Director | ||
| Kevin Trapp, Chief Commercial Officer | ||
| Mailys Ferrere, Non-Executive Director | ||
| Michel Rosen, Non-Executive Independent Chairman of the Board | ||
| David Schilansky, COO |
DBV Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is DBV Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.43 | |||
| Return On Asset | -0.22 | |||
| Operating Margin | (8.04) % | |||
| Current Valuation | 51.36 M | |||
| Shares Outstanding | 93.97 M | |||
| Shares Owned By Insiders | 6.50 % | |||
| Shares Owned By Institutions | 33.06 % | |||
| Price To Earning | 7.49 X | |||
| Price To Book | 1.24 X | |||
| Price To Sales | 28.00 X |
Pair Trading with DBV Technologies
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DBV Technologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DBV Technologies will appreciate offsetting losses from the drop in the long position's value.Moving against DBV Stock
| 0.87 | RMS | Hermes International SCA Earnings Call This Week | PairCorr |
| 0.83 | CS | AXA SA | PairCorr |
| 0.8 | CATR | Caterpillar Earnings Call This Week | PairCorr |
| 0.65 | TTE | TotalEnergies SE Earnings Call This Week | PairCorr |
| 0.6 | MC | LVMH Mot Hennessy | PairCorr |
The ability to find closely correlated positions to DBV Technologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DBV Technologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DBV Technologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DBV Technologies SA to buy it.
The correlation of DBV Technologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DBV Technologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DBV Technologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DBV Technologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DBV Technologies SA. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade DBV Stock refer to our How to Trade DBV Stock guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Complementary Tools for DBV Stock analysis
When running DBV Technologies' price analysis, check to measure DBV Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DBV Technologies is operating at the current time. Most of DBV Technologies' value examination focuses on studying past and present price action to predict the probability of DBV Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DBV Technologies' price. Additionally, you may evaluate how the addition of DBV Technologies to your portfolios can decrease your overall portfolio volatility.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |